Regulatory Approval

A new partnership highlights how regulatory pressure and data analytics are forcing skilled nursing facilities to adopt tech for safer, more efficient patient care.

A new AI system at Nashville's airport promises shorter lines and better security. We analyze the tech and the execution challenges behind the hype.

Eli Lilly's Zepbound secures a landmark approval for sleep apnea, moving beyond weight loss to redefine chronic disease management and challenge competitors.

Baptist Health's re-accreditation in the Cayman Islands is more than a quality seal. It’s a blueprint for a new economic and healthcare model in the Caribbean.

As 'forever chemicals' threaten NC water, PTRWA's new partnership with ROTEC brings cutting-edge filtration tech to safeguard public health and regional growth.

Insurtech firm PolicyMe has launched a unified platform promising to match any Canadian to the right life insurance in one session. Is this the innovation that finally cracks the industry's complexity, or a new tech facing a tough regulatory road?

Landsbankinn's latest NOK 250M bond issue isn't just funding; it's a calculated move to bolster regulatory capital and deepen its Nordic market footprint.

As Grown Rogue restarts a dormant Illinois facility, it’s not just planting seeds—it’s testing a capital-efficient strategy for winning in a crowded market.

Onix launches its Wingspan platform in Europe, introducing proprietary 'Semantic Twin' technology to help regulated industries navigate the EU's strict AI compliance maze.

Global broker ATFX secures key regulatory approval in Colombia, signaling a new phase of competition and opportunity in Latin America's booming fintech market.

Light AI's smartphone diagnostic tool enters a crucial New Zealand study, but can its innovative tech overcome financial pressures and regulatory hurdles?

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.

With a new critical illness feature, AuguStar Life is challenging the insurance industry's opaque benefit models with a clear, predictable lien system.

New Phase 3 data for Takeda's oveporexton shows it treats the root cause of narcolepsy, not just symptoms. A key FDA decision looms this year.

Calgary's Douglas Vermeeren faces new fraud charges despite a 10-year ban. His case reveals a high-stakes battle between regulators and persistent predators.

Anchorage Digital's custody of tokenized CETES marks a milestone, creating a federally regulated blueprint for bringing real-world sovereign debt onto the blockchain.

As Orca Bio builds a manufacturing empire from Sacramento to Princeton, it's not just preparing for a new drug launch—it's trying to solve the biggest puzzle in biotech.

A landmark study proves drones can safely transport human kidneys, a breakthrough that could slash wait times and save lives. But can we clear the regulatory hurdles?

SAP NS2's new high-security authorization for its cloud ERP allows it to challenge tech giants and accelerate the Pentagon's digital transformation.

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.